Tempus AI Inc

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Tempus AI Inc reports strong Q3 results and strategic acquisitions

Tempus AI Inc (TEM) showcased robust performance in Q3 2024, driven by revenue growth and strategic acquisitions, positioning the company for continued success.
While challenges like organizational readiness and market dynamics exist, the company's disciplined approach and strong partnerships present opportunities for sustained growth.
Overall, Tempus' focus on innovation, customer-centricity, and financial discipline sets a solid foundation for future growth and market leadership in the healthcare technology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI, Inc. founded in 2015, leverages AI for precision medicine, showing strong growth since its June 2024 listing, presenting a buying opportunity. The company boasts a vast clinical and molecular data library, advanced AI algorithms, and strategic partnerships with pharmaceutical giants like Merck and BioNTech. Despite profitability concerns and high cash burn, Tempus AI's revenue growth, strategic acquisitions, and unique data assets create a compelling long-term investment.

Tempus AI: Pioneering The Future Of Precision Medicine Through AI-Driven Innovation

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point of care solutions in oncology, to integrate its comprehensive genomic testing directly into Flatiron's cloud-based Electronic Medical Record (EMR) platform, OncoEMR® through the Molecular Profiling Integration (.

Tempus Molecular Profiling Integration Now Available Through Flatiron's OncoEMR®

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,” in JAMA Network Open. Tempus recently conducted a retrospective study of more than 5,500 patients with advanced non-small cell lung cancer (NSCLC) and found that concurrent RNA- and DN.

Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care

Tempus AI, Inc. (NASDAQ:TEM ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Liz Krutoholow – Investor Relations Eric Lefkofsky – Founder and Chief Executive Officer Jim Rogers – Chief Financial Officer Conference Call Participants Tejas Savant – Morgan Stanley Rachel Vatnsdal – JPMorgan Michael Ryskin – Bank of America Daniel Brennan – TD Cowen Ryan MacDonald – Needham Andrew Brackmann – William Blair Operator Thank you for standing by. My name is Briana, and I will be your conference operator today.

Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine abstracts were accepted for presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, which convenes in Houston, Texas, from November 6-10, 2024. “Presenting our latest research is a vital opportunity to showcase the advancements Tempus is making in harnessing the power of data and AI to drive im.

Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. IPS, which is now available for clinicians to order, is a multimodal biomarker that can be used as a prognostic indicator for adult patients with stage IV and metastatic pan-solid tumors who are already considered candidates for immune checkpoint inhibitor (.

Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test

TEM's third-quarter results reflect strong segmental performance. However, the company continues to incur losses at the operational level.

Tempus Stock Declines Despite Q3 Earnings & Revenues Beat Estimates

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter that ended September 30, 2024. The company also announced that it has entered into an agreement to acquire Ambry Genetics, a leader in genetic testing that aims to improve health by understanding the relationship between genetics and disease. Revenue increased 33.0% year-over-year to $180.9 milli.

Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The company's conference call that was previously scheduled for November 7, 2024 has been canceled. The call will feature Tempus.

Tempus to Report Third Quarter 2024 Financial Results on November 4

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, and Northwestern Medicine, Chicago's premier integrated academic health system, today announced a collaboration that aims to explore the application of artificial intelligence in clinical care and research. The collaboration, which is expected to span across several disease conditions over time, will start with the Northwestern Medicine Bluhm Cardiovascular Institute, a nationally recognized destinatio.

Tempus and Northwestern Medicine Announce Collaboration to Bring Practical Application of AI to Healthcare

Tempus AI, Inc, a healthcare technology company, has shown DECENT gains since its listing in June, outperforming the Nasdaq and AI-themed stock portfolios. TEM aims to leverage AI and ML and revolutionize healthcare diagnostics, a space which has large gaps and is relatively untapped. Despite an impressive revenue profile and a burgeoning data licensing vertical, TEM remains a long way off profitability and faces high operating cash burn and SG&A expenses.

Tempus: Attempting To Lead The AI Revolution In Healthcare

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursday, November 7, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast w.

Tempus to Report Third Quarter 2024 Financial Results on November 7

TEM's latest expanded partnership is likely to leverage multimodal real-world datasets and biological model systems in oncology R&D.

Tempus Stock Up Following Collaboration Expansion in Oncology R&D

Takeda Pharmaceutical

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaboration with Takeda (TSE:4502/NYSE:TAK) that takes a data-first approach to research and development, with the aim of enhancing Takeda's oncology research and development efforts. After an initial collaboration that leveraged Tempus' de-identified multimodal datasets, this new agreement will expand upon.

Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced four abstracts were accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2024, which convenes in Barcelona, Spain, from September 13-17, 2024. "ESMO provides a great platform to share our recent research and advancements with the global oncology community, foster further collaboration, and drive.

Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the beta launch of a patient-facing app, olivia, an AI-enabled personal health concierge to empower individuals to holistically organize, manage, and proactively take control of their own health data. olivia, which is currently only available to beta users, leverages generative AI to provide patients and their caregivers persona.

Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients

BioNTech SE

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM, “Tempus”), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a multi-year collaboration with BioNTech SE (Nasdaq: BNTX, “BioNTech”), a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. This collaboration leverages Tempus' robust multimodal datasets in support of BioNTech's next-generation oncology pipeline. Under this.

Tempus Announces Real World Data Collaboration with BioNTech

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4th, held in New York, NY. Tempus Founder and CEO, Eric Lefkofsky, will speak in a fireside discussion at the conference on Wednesday, September 4, 2024 at 8:30 a.m. ET. About Tempus Tempus is a technology company advancing precision medicine.

Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Delcath Systems

In this article, Seeking Alpha editors highlight 12 ideas published last week focused on stocks with less coverage on our platform. Energy ideas are prevalent in this edition with articles highlighted on uranium development, oil & gas, and clean energy companies. Healthcare-related stocks are in focus as well, with a couple of biotech picks, a skilled nursing facility operator, and a healthcare technology company included.

Undercovered Dozen: Delcath Systems, Bavarian Nordic, Tempus AI, Journey Energy +

In just ten days, shares of the mid-cap healthcare stock Tempus AI NASDAQ: TEM have gone from down 4% to up nearly 60% in 2024. Famed investor Cathie Wood recently increased her allocation to the company through the ARK Invest family of funds.

Biotech Stock Soars 60% in 2024: Cathie Wood's Bold Investment

The recently listed company expanded its shareholding in a biotech. It now owns over 19% of biotech Personalis' common equity.

Why Tempus AI Stock Skyrocketed Nearly 22% Today

Tempus AI provides an end-to-end diagnostic platform connecting clinical, molecular, and image data for physicians and pharmaceutical companies. The company's key competitive advantages include broad data collection, a genomics platform, and intelligent diagnostics, positioning Tempus uniquely in the healthcare technology industry. Recent financial results show 25% year-over-year revenue growth, with Softbank's investment indicating disruptive potential in healthcare diagnostics and precision medicine.

Tempus AI: Deploying AI In Precision Medicine; Initiate With 'Buy'

Cathie Wood, a prominent advocate for innovative technologies, is making a bold bet on artificial intelligence with her latest investment in Tempus AI Inc. (NASDAQ: TEM).  Known for her strategic focus on transformative technologies, Wood's decision to heavily invest in Tempus reflects her confidence in the company's potential within the burgeoning AI health-tech sector.

Cathie Wood bets big on Tempus AI: Is it the next big thing in health-tech?

BERGEN, Norway , Aug. 21, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced financial results for the quarter and half year ended June 30, 2024, and provided a business update. Highlights, including post period: BGBC016 1L NSCLC STK11m study continues to progress as planned.

BerGenBio Second Quarter Results 2024: Solid clinical and financial progress

Advanced Micro Devices

Micron Technology

We all know by now that compound interest is hard to visualize. As early as 1256 AD, storytellers began recording the wheat and chessboard problem.

News for Tempus AI Inc Stock (TEM)